Emerging research findings about B cell biology need to be harnessed for developing rationally-designed vaccines against HIV-1. This FOA will support mechanistic studies with the goal of informing novel immunization strategies for generating optimal/preferable B cell responses against HIV-1.
This FOA will also support studies focused on acquiring a deeper understanding of the mechanisms by which current HIV-1 vaccine platforms induce Ab responses and the development of strategies to improve these responses. HIV-1 vaccine research is entering a time of great opportunity, and integrated approaches that dissect the mechanisms governing vaccine-induced, antigen-specific immune responses in humans will be valuable in developing an effective HIV-1 vaccine.
Specific Areas of Research Interest
This FOA is restricted to hypothesis-driven mechanistic studies. Applicants are strongly encouraged to contact, well in advance of submission, the Scientific/Research Contact to discuss the appropriateness of the scope of the proposed project.
Areas of interest include, but are not limited to, the following:
- Acquire a better understanding of the consequences of modulating innate and/or T cell pathways on the humoral immune response against HIV-1.
- Explore approaches to direct B cell fate for the generation of long-term memory and persistent Ab production. Examples may include previously established adjuvants, immunomodulators, and antigen delivery systems, either alone or in combination.
- Identify ways to induce and maintain B cell lineages in relevant anatomical niches following vaccination against HIV-1.
- Acquire an understanding of the relationship between the subpopulations of B cells generated during vaccination and affinity maturation or the durability of the anti-HIV-1 Ab response.
- Studies that benchmark the response to HIV-1 immunogens against the response to other infectious agents or model systems.
- Studies that employ multiparametric analysis (e.g. specificity, class, affinity, post-translational modifications) for profiling Ab responses to HIV-1 immunogens and the application of this knowledge to regulate desirable B cell responses in improved HIV-1 vaccine platforms.
- Acquire an understanding of the antigenic variation, vaccine design (e.g. protein vs. DNA vs. live vector) and immunization strategies (e.g. prime-boost, differential dosing and number of immunizations, and intervals) for programming Ag-specific B cells at prime and/or during recall.
- Studies designed to harness the role of B cells in regulating T cell immunity against HIV-1.
- Studies to modulate desirable Ab-effector functions with durable protective properties against HIV-1 acquisition.
- Studies exploring immunocomplexes for the maturation of the antibody response against HIV-1.
SOURCE: National Institute of Allergy and Infectious Diseases (NIAID)
APPLICATION DEADLINE: Letter of Intent: 2/17/16. Application: 3/17/16 by 5 pm local time of applicant organization.
$ AVAILABLE: NIAID intends to commit $2 million in FY2017 to fund two to three awards.
ELIGIBILITY: * Public/state/private controlled institutions of higher education.
* Hispanic-serving institutions.
* Historically Black Colleges and Universities (HBCUs).
* Tribally Controlled Colleges and Universities (TCCUs).
* Alaska native and native Hawaiian serving institutions.
* Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
* Nonprofits with or without 501(c)(3) IRS status (other than institutions of higher education).
* Small businesses.
* For-profit organizations (other than small businesses).
* State governments.
* County governments.
* City or township governments.
* Special district governments.
* Indian/Native American tribal governments (federally recognized and other than federally recognized).
* Eligible agencies of the federal government.
* U.S. territories or possessions.
* Independent school districts.
* Public housing authorities/Indian housing authorities.
* Native American tribal organizations (other than federally recognized tribal governments).
* Faith-based or community-based organizations.
* Regional organizations.
* Non-domestic (non-U.S.) entities (foreign institutions).
PURPOSE: The objective of this Funding Opportunity Announcement (FOA) is to solicit hypothesis-driven, multidisciplinary research to elucidate the complexities and developmental plasticity of B cells associated with the induction of potent, durable, adaptive immune responses against HIV-1.
CFDA: 93.855, 93.856
CONTACT: Please see URL for multiple contacts.
For more information see http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-15-055.html
From CDC National Prevention Information Network’s (NPIN) HIV/Hepatitis/STD/TB Funding Information email, 10/29/15
Subject(s) HIV/AIDS research